Vertisal

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vertisal

Quick Facts

Property Description
Active ingredient Metronidazole
Form Tablet, Solution for Infusion, Vaginal Gel, Suppository
Pharmacological class Anti-infective Agent, Nitroimidazole Derivative
Common use Systemic and localized control of specific microbial infections
Origin Synthetic drug

What Type of Medicine is Vertisal and What is it Made Of?

Vertisal is a synthetic drug classified as an Anti-infective agent, belonging to the Nitroimidazole derivative group of antibiotics. Its composition is defined by the single active ingredient, Metronidazole (the INN), which is a key chemical entity recognized for its specific efficacy against oxygen-sensitive microbial pathogens. This compound has been clinically recognized for its reliable pharmacological properties. The final preparation is a prescription-only (Rx) medicine that combines Metronidazole with the necessary pharmaceutical bases or solutions for delivery.

What Forms of Vertisal are Available?

To ensure effective targeting, Vertisal is supplied in several distinct pharmaceutical preparations, enabling both systemic and localized delivery. These dosage forms include the oral tablet for systemic administration, the solution for infusion for intravenous use, and local options such as the vaginal gel or suppository for topical therapy. The availability of these various forms allows the medicine to be used for a wide range of microbial issues, from those requiring body-wide distribution to those concentrated at a specific site.

What is the General Purpose of Vertisal?

The general purpose of Vertisal is to address infectious processes by exerting powerful selective toxicity against two specific classes of harmful microorganisms: anaerobic bacteria and protozoa. This targeted function is characterized by the compound's mechanism of being activated predominantly in low-oxygen environments. This chemotherapeutic agent is recognized for its reliable action, underscoring its established importance in public health for controlling infections.

Regulatory References

  1. Metronidazole Mechanism of Action (NIH StatPearls)

What side effects are possible with Vertisal?

Possible Side Effects and Safety Information

The safety profile for Vertisal (Metronidazole) is officially categorized by the potential effects on major organ systems. The spectrum of documented adverse reactions ranges from commonly reported effects to rare, serious events.

Documented Adverse Reactions

Frequency Category Associated Adverse Reactions (Examples)
Common Nausea, metallic or unpleasant taste, headache, vomiting, diarrhea, abdominal cramping.
Not Known Encephalopathy, aseptic meningitis, optic neuropathy, peripheral neuropathy, and severe skin reactions.

Safety data lists effects across several System-Organ Classes, including Gastrointestinal Disorders (e.g., stomatitis, glossitis) and Nervous System Disorders (e.g., dizziness, confusion, seizures). Serious adverse reactions explicitly documented in regulatory information include convulsive seizures, encephalopathy, and severe cutaneous reactions such as Stevens-Johnson Syndrome.

Safety Constraints and Considerations

Official labeling contains specific constraints. The consumption of alcohol or propylene glycol during therapy is restricted due to the potential for a severe disulfiram-like reaction (flushing, vomiting, headache). The drug should be used with particular caution in patients with a history of blood dyscrasias.

Population-Specific Notes: Patients with severe hepatic impairment (liver function) must be monitored closely due to potential drug accumulation. Furthermore, the use of Metronidazole is contraindicated in individuals with Cockayne Syndrome due to the high risk of fatal hepatotoxicity. Monitoring of blood cell counts is advised for treatments that extend beyond ten days.

Overdose and Emergency Response

Overdose Scope

Category Official Regulatory Statement
Documented overdose presentations Nausea, Vomiting, Ataxia, Convulsive seizures, and Sensory peripheral neuropathy.
Physiological systems affected Central Nervous System (CNS) effects (e.g., encephalopathy, seizures), Hepatic (acute liver failure), and Severe Cutaneous Adverse Reactions (SCARs).
Dose-related or exposure-related factors Manifestations have been reported following both large, single-dose exposures (up to 15 g) and high-dose, extended courses of therapy.
Population-specific overdose notes Severe irreversible hepatotoxicity is noted in patients with Cockayne syndrome. Monitoring for adverse events is recommended for geriatric patients and those with severe hepatic impairment or end-stage renal disease.
Emergency-response statements Management consists of symptomatic and supportive therapy as no specific antidote is known. Therapy must be discontinued if abnormal neurological signs or SCARs develop.
When immediate medical help is required Seek immediate medical attention for suspected overdose. Urgent care is required if severe symptoms occur, such as seizures, collapse, trouble breathing, or signs of brain involvement (e.g., stiff neck, confusion, difficulty speaking).

Overdose Classifications (High-Level)

Category Official Regulatory Statement
Severity classification Defined by the presentation of serious outcomes, including Convulsive seizures, Encephalopathy, Aseptic meningitis, and Severe irreversible hepatotoxicity.
Regulatory basis FDA Prescribing Information, NHS Regulatory Guidance.

Resulting Overdose Structure

Official overdose statements:

  • Overdose may present with documented manifestations including nausea, vomiting, ataxia, convulsive seizures, and sensory peripheral neuropathy.
  • Life-threatening outcomes reported include encephalopathy, aseptic meningitis, and severe irreversible hepatotoxicity.
  • There is no specific antidote for the overdose; management is limited to symptomatic and supportive therapy.
  • Immediate medical attention is required for suspected overdose or if severe symptoms such as seizures, collapse, or confusion are observed.
  • Discontinuation of therapy is mandated if abnormal neurological signs or symptoms of a Severe Cutaneous Adverse Reaction develop.

Connection to the overall overdose profile (3 sentences): The regulatory documents define the Vertisal overdose profile by explicitly listing the neurological and gastrointestinal manifestations observed in cases of high exposure. They mandate immediate medical attention when severe or life-threatening symptoms such as seizures or collapse are observed, reflecting the drug's potential for serious CNS and hepatic toxicity. The absence of a specific antidote confirms that official management is strictly limited to supporting the patient through the manifested symptoms.

Therapeutic Uses of Vertisal

What Vertisal Treats: Main Uses and Benefits

Vertisal may be part of symptomatic management and is applied when appropriate across a variety of clinical contexts. It supports easing the overall symptom burden and helps maintain a sense of stability when discomfort is heightened or temporary functional strain occurs. The high-level approach to managing general distress and improving patient comfort falls under the broader clinical practice of supportive care.

Alleviating Acute Symptomatic Discomfort

Vertisal may assist with addressing symptom clusters that may become intense or disruptive, such as those related to physical discomfort. It provides support that contributes to easing the overall symptom load during phases of increased distress, particularly when supportive symptom management is appropriate. It is applied in addressing symptom clusters related to physical discomfort, systemic imbalance, or heightened physiological activity.

Supporting Stability in Fluctuating Conditions

This medication is commonly used to help with conditions characterized by periods of heightened symptoms or episodic manifestations. It helps manage symptoms that interfere with daily comfort and supports patients during episodes of heightened discomfort, helping to maintain a sense of stability. It is considered relevant in conditions associated with increased physiological stress or inflammatory or irritative states where functional stability becomes affected.

Quick Fact: Supports in managing Symptoms that Interfere with Daily Functioning

Eligibility and Restrictions for Use

Eligibility for Vertisal (Metronidazole)

The official eligibility profile for Vertisal is structured by regulatory authorities based on absolute prohibitions and conditional use requirements. The medicine is generally established for use in adults and pediatric patients for approved anti-infective indications.

Classification Population or Condition
Absolutely Contraindicated Prior hypersensitivity to metronidazole or nitroimidazole medicines. Patients with Cockayne Syndrome. Patients who have consumed disulfiram within the last two weeks or who cannot abstain from alcohol during and shortly after therapy [1.4, 2.4].
Restricted/Conditional Use Patients with severe hepatic impairment (Child-Pugh C) are eligible, but use requires a mandatory dosage reduction [1.3]. Patients with End-Stage Renal Disease and older adults require close monitoring for metabolite accumulation or adverse events [1.2, 2.1].
Age-Related Status Use is established for amebiasis in children, but is not established for many other indications in the pediatric population [4.1]. Newborn infants may require serum concentration monitoring due to a diminished capacity to eliminate the medicine [4.3].
Pregnancy/Lactation Use during pregnancy is permitted when clearly indicated, though some authorities do not recommend use for trichomoniasis during the first trimester [2.4]. Breastfeeding mothers are generally compatible with use, but temporary interruption may be advised to minimize infant exposure [2.5].

These regulatory classifications define which patient populations must not use the medicine and which require special precautions or monitoring to maintain eligibility.

What should I know about interactions with other medicines?

The official regulatory profile for Vertisal (Metronidazole) establishes specific restrictions based on its interaction patterns with certain medicinal products and substances.

Interaction Classifications (High-Level)

Classification Interacting Agents Official Interaction Outcome
Contraindicated Disulfiram Risk of psychotic reactions. Avoidance required for two weeks after Disulfiram use.
Contraindicated Alcohol/Propylene Glycol Risk of disulfiram-like reaction; avoidance required during therapy and for at least three days afterward.

Official Interaction Statements

  • Pharmacokinetic Interference: Vertisal may potentiate the anticoagulant effect of Warfarin and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time.
  • Exposure Modification: Co-administration with Lithium can lead to elevated serum concentrations of Lithium, requiring monitoring. Similarly, Vertisal is reported to increase plasma concentrations of Busulfan.
  • Metabolic Effects: Other agents, such as Phenytoin and Phenobarbital, are stated to accelerate Vertisal's elimination, which reduces its plasma concentration.
  • Laboratory Interference: Vertisal may interfere with certain serum chemistry laboratory values due to assay constraints.
  • Population Note: Exposure (AUC) to Vertisal and its active metabolite is officially reported to be higher in patients with severe hepatic impairment and in geriatric patients over 70 years old.

Mechanism of Action

How Vertisal Works


Triggering Selective Toxicity via Reductive Activation

The action of Vertisal is based on the mechanism of selective toxicity, a constraint that targets specific microbial characteristics. The compound functions as an inactive prodrug that must undergo reductive activation within the target cell. This transformation is carried out by nitroreductase enzymes and low-redox potential electron carriers (like ferredoxin), which are present only in anaerobic bacteria and protozoa. This highly specific activation ensures the drug's destructive mechanism is triggered only within the pathogenic cell, a constraint that defines the specific microbial spectrum against which the mechanism is functionally applied.


Irreversible Microbial DNA Disruption

Once activated, the drug forms highly reactive cytotoxic intermediates (free radicals) that immediately attack the essential biological components of the microbe. The primary site of action is the Microbial DNA, where the intermediates cause covalent binding and subsequent strand breakage. This irreversible damage prevents the cell from replicating or repairing itself, leading to the rapid cellular termination (bactericidal/protozoacidal) and the subsequent resolution of cellular integrity within the susceptible pathogen.


Functional Limits Due to Oxygen Antagonism

The mechanism is strictly bound by the surrounding environment. The presence of oxygen acts as a chemical antagonist by immediately neutralizing the active, intermediate radicals and cycling them back to the inactive parent drug. This oxygen antagonism is a key mechanistic limitation, resulting in the functional loss of the mechanism against bacteria that thrive in oxygen-rich (aerobic) conditions.

Dosage and Administration Information

Official Administration Guidelines for Vertisal

Vertisal (Metronidazole) is administered according to specific protocols to ensure standardized use. Its administration methods include oral (tablets, capsules, suspension), intravenous (IV) infusion, and local application (vaginal gel or suppository).

Standard Dosing and Frequency

For systemic anaerobic infections, the usual adult maintenance dose is 7.5 mg/kg administered every 6 hours, with a maximum daily dose not to exceed 4 grams. Other oral courses may vary, such as 250 mg three times daily or a 2 g single dose for certain indications, with typical treatment duration lasting 7 to 10 days. Intravenous infusion must be administered slowly over 30 to 60 minutes.

Procedural and Population Constraints

Specific instructions govern how the medicine is taken:

  • Food Timing: Immediate-release oral forms may be taken with or without food. However, the extended-release tablet (750 mg) must be taken without food (one hour before or two hours after a meal).
  • Tablet Integrity: Extended-release tablets must be swallowed whole and should not be crushed, broken, or chewed.
  • Hepatic Adjustment: A 50% dose reduction is required in patients with severe hepatic impairment (Child-Pugh C).
  • Dialysis: For patients undergoing hemodialysis, supplementation of the dose should be considered following the dialysis session due to drug removal.

The entire usage protocol is framed by these defined parameters of route, dose, frequency, and specific handling.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Vertisal (Metronidazole)


Evidence for Use in Systemic Anaerobic Bacterial Infections

Research into the use of Vertisal for systemic anaerobic bacterial infections has been applied in studies examining conditions characterized by fluctuating or episodic manifestations within the body, such as infections related to the abdomen or pelvis. The evidence base includes numerous randomized controlled trials (RCTs) and systematic reviews which examined the medicine in relation to other active treatments or combinations of treatments. Studies monitored outcomes related to systemic or functional imbalance, such as the disappearance of clinical signs of infection and the measurement of bacteria clearance. Findings describe patterns observed in these studies, where patients was observed in over defined time intervals, often up to several weeks following the end of therapy. However, the results apply only to the populations studied, and the research often involved the medicine being used alongside other antibiotics, which means separating its specific contribution can be challenging in certain settings.


Evidence for Use in Protozoal Infections

The research for this indication is built upon multiple RCTs designed to examine the medicine against other active treatments or standard care. Studies monitored outcomes related to systemic or functional imbalance and the measurement of parasite absence. Studies monitored patient-reported outcomes describing perceived discomfort and the rate at which the infection returned. Findings indicate that, when applied in studies examining patient-reported experiences, studies monitored the absence of the parasite in the study populations. Nevertheless, research is ongoing regarding reports of reduced microbial susceptibility, particularly in cases of T. vaginalis, which suggests research findings may vary over time and location.


What is Still Uncertain About the Research for Vertisal

The research contributes to the broader evidence landscape, yet certain aspects remain under investigation. A key uncertainty relates to comparative evidence is lacking for some of the newer treatment options, meaning the evidence base must be frequently reviewed. Furthermore, evidence quality varies across studies, and the issue of rising microbial resistance to the medicine was observed in some studies, which highlights a significant area for future research. Finally, while research provides insight into short-term changes, there is limited information for long-term outcomes and the factors that influence infection recurrence following treatment.

Key Studies & References

  1. Metronidazole (StatPearls - NIH Bookshelf)
  2. IDSA/SHEA Clinical Practice Guideline for Clostridioides difficile Infection: 2017 Update (Used for CDI Evidence)

Frequently Asked Questions (FAQ)

Common questions about Vertisal (FAQ)


Q: Is Vertisal used for more than just the condition it was approved for?

Official documents define the established uses of Vertisal to specifically target infections caused by anaerobic bacteria and protozoa. Its inclusion on the World Health Organization's Essential Medicines List since 1977 highlights its role in treating these microbial infections, aligning with the regulatory approvals granted for its use.


Q: How long does it typically take to start feeling the effects of Vertisal?

Information on the medicine's movement in the body indicates it is generally absorbed within a few hours. However, the official documents do not define a specific timeline for when a change in symptoms should be expected; this often varies based on the individual and the condition being addressed.


Q: Can Vertisal be taken with food, or does it have to be on an empty stomach?

This depends on the specific form of the medicine prescribed. Immediate-release oral forms can generally be taken with or without food. However, if you are prescribed the extended-release tablet, the official administration instructions describe that it is used without food, which is defined as taking it one hour before or two hours after a meal.


Q: What should I do if I miss taking a dose of Vertisal?

Regulatory patient information describes that a missed dose may be taken as soon as it is remembered. However, if it is almost time for your next scheduled dose, the missed dose should be skipped. The regular dosing schedule is then continued, and taking a double dose to compensate for a missed dose should be avoided.


Q: Are there any common over-the-counter supplements that should be avoided while on Vertisal?

Official interaction statements provide specific warnings about avoiding alcohol, propylene glycol, and certain prescription medications while using Vertisal. The regulatory documents do not provide comprehensive statements covering every common over-the-counter supplement or herbal product.


Q: Is Vertisal safe to use for older adults or elderly people?

Vertisal is established for use in older adults. However, official information notes that use in this population requires close monitoring for potential accumulation of the medicine or its byproducts. This is because people over 70 years old have been reported to have a higher exposure to the medicine.


Q: What happens if I stop taking Vertisal suddenly?

Official information emphasizes that the medicine is generally intended to be completed according to the prescribed course. Discontinuing the medicine prematurely is a factor that has been described in relation to infection recurrence.


Q: Can Vertisal be used by people who have existing liver or kidney conditions?

Use is conditional, according to official eligibility information. Patients with severe hepatic (liver) impairment require a mandatory 50% reduction in the dose. Additionally, patients with end-stage renal (kidney) disease or those undergoing hemodialysis require close monitoring and may need dose adjustments after dialysis sessions.


Q: Is it possible for Vertisal to cause weight changes (gain or loss)?

Weight loss is noted in some patient reports as a less common event in safety surveillance data. More commonly, regulatory documents list gastrointestinal effects like nausea, vomiting, and loss of appetite, which could indirectly lead to changes in body weight.


Q: What is the shelf life of Vertisal, and how should it be stored?

Official regulatory guidance states that Vertisal must not be used after the expiry date printed on the package. The tablets and intravenous solution are stored at a controlled room temperature, specifically between 20 C and 25 C (68 F to 77 F), and the product is kept out of the sight and reach of children.


Q: How quickly does Vertisal leave the body?

Studies show that the elimination half-life of Vertisal is approximately eight hours. This indicates that it takes roughly 44 hours (or about 5.5 times the half-life) for the medicine to be nearly eliminated from the body for individuals with typical renal function.


Q: Do I need to have regular blood tests while I am taking Vertisal?

Official safety information advises that monitoring of blood cell counts is required if the treatment extends beyond ten days. Additionally, close monitoring of liver function tests is required for patients who have severe liver conditions or who have Cockayne Syndrome.


Q: Why do some people say they felt worse when they first started taking Vertisal?

Regulatory safety documents list commonly reported adverse reactions that may contribute to an initial feeling of discomfort. These include temporary effects such as nausea, vomiting, metallic or unpleasant taste, and headache, which are often related to the digestive or nervous systems.


Q: Can Vertisal be crushed, split, or chewed?

The administration instructions depend on the form. Specifically, the extended-release tablets are intended to be swallowed whole and are not to be crushed, broken, or chewed. The regulatory labeling provides precise instructions for all specific forms.


Q: Is Vertisal available as a generic version?

Yes, the active ingredient in Vertisal, which is Metronidazole, is widely available in generic versions. These generic products are approved by regulatory bodies, such as the FDA, as therapeutic equivalents to the brand-name medicine.


Q: Are there any dietary restrictions mentioned in the official documents for Vertisal?

The most important restriction mentioned in official regulatory documents is the absolute avoidance of alcohol and products containing propylene glycol. This constraint is in place because mixing these substances with Vertisal can cause a severe reaction that includes flushing, vomiting, and headache.


Q: What if I forget where I stored my Vertisal, and it gets too hot or too cold?

Official storage instructions specify that Vertisal must be maintained at a controlled room temperature (between 20 C and 25 C) and protected from light. Storing the medicine outside of these required temperature ranges may pose a risk to its stability or quality.


Q: Are there any specific lifestyle changes that are recommended while using Vertisal?

The only lifestyle constraint explicitly described in regulatory documents is the avoidance of alcohol and any products containing propylene glycol during the course of treatment and for a period of time after the last dose.


Q: What happens if a child accidentally takes Vertisal?

All forms of Vertisal must be stored out of the sight and reach of children. Accidental ingestion poses a potential risk of overdose, and regulatory documents suggest this situation warrants urgent attention.


Q: Is Vertisal tested on animals before being approved for human use?

Yes, official safety documents include nonclinical toxicology data from animal studies. Regulatory bodies, such as the FDA, note that Vertisal (Metronidazole) has been shown to be carcinogenic in mice and rats, which is why it carries a specific warning and its use is restricted to approved indications.


Q: Is Vertisal suitable for teenagers or children?

According to official documentation, the use of Vertisal is established for treating amebiasis in children. However, its use is not established for many of its other indications in the pediatric population, and newborn infants may require additional monitoring for drug elimination.


Q: Do the side effects of Vertisal usually go away after a few weeks?

While regulatory data on common side effects, such as nausea and metallic taste, do not typically provide a defined timeline for resolution, these common effects are generally expected to be temporary. They often lessen as the body adjusts to the medicine during the treatment period.


Q: Is it true that Vertisal should not be mixed with certain juices like grapefruit juice?

Official regulatory documents and patient information labels do not contain a specific restriction or warning against combining Vertisal with grapefruit juice. The only food-related substances explicitly restricted are alcohol and propylene glycol.

How should Vertisal be stored and disposed of?

How to Store and Dispose of Vertisal?

Official regulatory labeling dictates specific conditions to maintain the stability and safety of Vertisal (Metronidazole).

Storage Requirements

Vertisal tablets and the solution for infusion must be stored at a controlled room temperature, specifically between 20 C and 25 C (68 F to 77 F). The intravenous solution must be protected from light and must not be refrigerated, as this condition can cause product precipitation. All forms of the medicine must be stored out of the sight and reach of children.

Handling and Disposal

The medicine should remain in its original container, and the IV solution must be visually inspected for any discoloration or precipitate prior to use, which are signs of instability. Unused or expired Vertisal must not be disposed of via wastewater or household trash. Disposal must occur in accordance with local procedures for pharmaceutical waste, such as through an established drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vertisal found in:

A-Z Index: